- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Brexpiprazole, Sertraline, Placebo
- Drug · Other
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 591 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–18
of 18
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Brexpiprazole, Sertraline, Placebo
- Drug · Other
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 935 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 35 more
- Conditions
- Suicide
- Interventions
- Stage 1 Treatment as usual (TAU), Stage 1 CAMS, Stage 2 CAMS, Stage 2 Dialectical Behavioral Therapy (DBT)
- Behavioral
- Lead sponsor
- University of Nevada, Reno
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Multiple Sclerosis
- Interventions
- Ocrelizumab, Antihistamine, Methylprednisolone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 769 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 24
- States / cities
- Homewood, Alabama • Phoenix, Arizona • Irvine, California + 21 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
- Interventions
- Vixarelimab, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
- Conditions
- Suicide
- Interventions
- Treatment As Usual (TAU), Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1, Dialectical Behavior Therapy (DBT) - Phase 2, Maintenance/Monitoring - Phase 2, Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 4
- States / cities
- Reno, Nevada • New Brunswick, New Jersey • Durham, North Carolina + 1 more
- Conditions
- Suicidal Ideation, Suicide, Attempted, Coping Skills, Depression, Anxiety, PTSD
- Interventions
- Group Brief Cognitive-Behavioral Therapy (G-BCBT), Dialectical Behavior Therapy (DBT) Skills Group
- Behavioral
- Lead sponsor
- University of North Carolina, Charlotte
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Portsmouth, Virginia
- Conditions
- Primary Mitochondrial Myopathy
- Interventions
- Bocidelpar, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 11
- States / cities
- La Jolla, California • Stanford, California • Aurora, Colorado + 7 more
- Conditions
- Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Interventions
- Acolbifene Hydrochloride, Biospecimen Collection, Mammography, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Duarte, California • Chicago, Illinois • Kansas City, Kansas + 1 more
- Conditions
- Suicide
- Interventions
- TAU - Phase 1, CAMS - Phase 1, DBT - Phase 1 and 2, CAMS - Phase 2, DBT - Phase 2
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Reno, Nevada • New Brunswick, New Jersey • Durham, North Carolina + 1 more
- Conditions
- Multiple Sclerosis
- Interventions
- Ocrelizumab, Antihistamine, Methylprednisolone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 864 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 25
- States / cities
- Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 22 more
- Conditions
- Migraine
- Interventions
- Rimegepant, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 93
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 86 more
- Conditions
- Alzheimer Disease
- Interventions
- sabirnetug, Placebo
- Drug
- Lead sponsor
- Acumen Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 44
- States / cities
- Carlsbad, California • Fullerton, California • Irvine, California + 40 more
- Conditions
- Non-Suicidal Self Injury, Suicide, Self-harm, Emotion Regulation
- Interventions
- Dialetical Behavioral Therapy for Adolescents
- Behavioral
- Lead sponsor
- The Catholic University of America
- Other
- Eligibility
- 10 Years to 21 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Ublituximab, Umbralisib, Venetoclax
- Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 45 more
- Conditions
- Breast Cancer
- Interventions
- Bevacizumab, Docetaxel, Trastuzumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Breast Cancer, Locally Advanced Breast Cancer, Neoadjuvant Chemotherapy, HER2-positive Breast Cancer, Triple Negative Breast Cancer, TNBC, Triple Negative Breast Cancer
- Interventions
- CEDM, CEDBT, Omnipaque 350mgI/mL Solution for Injection
- Diagnostic Test · Drug
- Lead sponsor
- Alison Stopeck
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Stony Brook, New York